US3903069A - Polypeptides obtained by modification of porcine or bovine insulin - Google Patents

Polypeptides obtained by modification of porcine or bovine insulin Download PDF

Info

Publication number
US3903069A
US3903069A US420573A US42057373A US3903069A US 3903069 A US3903069 A US 3903069A US 420573 A US420573 A US 420573A US 42057373 A US42057373 A US 42057373A US 3903069 A US3903069 A US 3903069A
Authority
US
United States
Prior art keywords
insulin
porcine
enzyme
bovine
des
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US420573A
Other languages
English (en)
Inventor
Harold Gregory
Peter Leslie Walton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Application granted granted Critical
Publication of US3903069A publication Critical patent/US3903069A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Definitions

  • the insulin normally used is obtained from pigs. so-called porcine insulin or from cows, so-called bovine insulin.” It is also known that administration of either porcine insulin or bovine insulin, as normally available. often causes an antigenic response. In humans. this antigenic response can lead. over a prolonged period of dosing. to an increase in the daily dose required by the diabetic patient to control the disease.
  • porcine or bovine insulin as normally available. is treated with a lysine specific aminoendopeptidase. that is a peptidase which cleaves a polypeptide at the peptide link attached to the amino group of lysine and does not require the lysine reside to be at the C-terminus of the peptide chain, then the products obtained are as potent as porcine or bovine insulin in causing a hypoglycaemic response, and furthermore. each of them causes a significantly smaller production of antibodies which bind insulin-like materials on subsequent administration than does the initial porcine or bovine insulin respectively.
  • the enzyme removes the dipeptide L-lysyl-L alanine from the C- terminus of the 8 chain of the porcine or bovine insulin, and the polypeptides so obtained have not been described previously.
  • lysine specific aminoendopeptidases there may be mentioned the enzyme AM protease and the enzyme myxobacter AL-l protease II. v
  • the enzyme AM protease may be obtained from the mature fruiting bodies of the fungus Armillaria melleu as fully described and claimed in UK. Pat. specification No. 1,263,956.
  • the enzyme may also be obtained. slightly more conveniently. by a modification of the procedure described in UK. 1.263.956 in which the chromatography step (iv) is carried out in two stages: firstly by adsorbing the crude enzyme on carboxymethyl cellulose at pH 4.5. and then eluting it with a pH 5.5 buffer and secondly by applying the concentrated eluate to the column described in step (iv) in the above patent.
  • the enzyme myxobacter AL-l protease ll may be obtained from nryxvhucrer strain AL-l as described by Wingard. Matsueda and Wolfe in the Journal of Bacteriology, Vol. l l2. pages 940-949.
  • the exposure of the porcine or bovine insulin to the lysine specific amino-endopeptidase may be carried out with the enzyme simply dissolved in the aqueous medium. or it may be carried out with the enzyme bound to a supportwhich may or may not be soluble in the aqueous medium.
  • the rate and extent of the reaction between the insulin used as starting material and the enzyme is dependent upon the enzyme/substrate ratio.
  • the pH and temperature of the incubation medium the concentration of insulin and the time of incubation. In general. of course. the time taken to cleave lysyl-alanine from the insulin used as starting material is shortened by an increase in either the concentration of the insulin or the enzyme/substrate ratio.
  • variation in the pH or temperature of the incubation medium affects the Phe.Val .Asn. G1n.His .Leu.Cys Gly .Ser.His .Leu.Va1 G1u.Ala.Leu.Tyr.Leu.Val Cy Gly. Glu
  • the polypeptide wherein R is alanine and R is val-' ine differs from bovine insulin only in that the B chain lacks the C-terminal lysyl and alanyl residues. It can therefore be named as des-Lys -Ala bovine insulin, and this name will be used hereafter.
  • a process for the preparation of des-Lys Ala""-procine insulin from procine insulin or of des- Lys -Ala*"-bovine insulin from bovine insulin which comprises exposing the porcine or bovine insulin in an aqueous medium to the action of a lysine specific amino-endopeptidase followed by separation of the des-l.ys -Ala -porcine insulin or des-Lys'-"-Alabovine insulin from the remaining enzyme and lysylalanine.
  • the reaction will also proceed at a pH of the incubation medium from 3 to 10. and at a temperature from 10C. to 60C. With a given concentration of insulin, the reaction is fastest at a pH of from 4 to 9, but in the lower part of this pH range. the solubility of the insulin is relatively low so that a greater production of enzyme treated insulin is attainable at pH values in the higher part of the above range where the solubility of the insulin is greater. Accordingly. preferred reaction conditions to obtain essentially complete cleavage of lysyl-alanine in a relatively shoit period. for example 3-12 hours, are the use ofa concentration of insulin near to its solubility in the incubation medium.
  • the reaction conditions are very similar to those which may be used with AM protease; an enzyme/substrate ratio as low as 1/ 10,000 may be used at a pH from 4 to 1 O at a temperature from 2 5C. to 75C.
  • Preferred conditions are the use of a concentration of insulin near to its solubility in the incubation medium, a pH of from 6 to 9, a temperature from 30C. to 50C., and as low an enzyme/substrate ratio as possible, for example l/1,000 or less.
  • Metal ions for example calcium or magnesium may be included in the incubation medium.
  • the reaction may be carried out using the enzyme bound, preferably covalently, to a support.
  • a support A variety of supports and methods of attach ment are possible, and for details, a review of E. Katchalski Biochemical Aspects of Reactions on Solid Supports ed. G. R. Stark, Academic Press 1971, should be consulted.
  • One convenient method of attaching AM protease to a support is to activate agarose gel beads with cyanogen bromide, with or without spacer groups derived, for example, from hexylamine or hexanoic acid, and then allow the activated agarose to react with AM protease.
  • the agarose gel beads may be activated using 2,4-dichloro-6-carboxymethylamino-s-triazine as coupling agent.
  • Another useful alternative is the use of carboxymethyl cellulose hydrazide.
  • the required des-Lys -Ala"-porcine (or bovine) insulin may be separated from the other components of the incubation mixture by any conventional technique for the separation of polypeptides, but the use of a molecular sieve technique is particularly convenient.
  • the aqueous medium remaining after all the starting insulin has been degraded may be filtered through a column of cross-linked dextran gel or a polyacrylamide gel suitable for fractionating compounds of molecular weight 5,000l0,000 at any convenient pH, preferably removed from, and preferably substantially below, the isoelect ric point of the polypeptides, and the column eluted with a buffer composed of components which are volatile on freeze drying under high vacuum, for example aqueous acetic acid, ammonium carbonate or ammonium acetate, to give the desired product which is isolated by freeze drying the eluate.
  • a buffer composed of components which are volatile on freeze drying under high vacuum for example aqueous acetic acid, ammonium carbonate or ammonium acetate
  • separation of the required polypeptide from enzyme may be carried out by filtration in the normal way if the support is insoluble or using a filter for high polymers if the support is soluble in the aqueous medium.
  • porcine or bovine insulin even porcine or bovine insulin which has been crystallised several times, contains other polypeptides as impurities.
  • These impurities are usually present in an amount being 3-57: by weight of thewhole, and consist of materials such as pro-insulin, pro-insulin fragments and glucagon which can be difficult to separate from the insulin.
  • the impurities present in an insulin preparation contribute to its antigenicity
  • exposure of the insulin preparation to a lysine specific amino-endopeptidase can affect the antigenicity of the starting material by modifying the structure of the principal component and by reducing the amount of impurities.
  • a process for the conversion of porcine or bovine insulin as normally available into a product having insulin-like activitybut being less effective in causing the production of antibodies which bind insulin-like materials on subsequent administration than does the starting material which comprises exposing the porcine or bovine insulin in an aqueous medium to the action of a lysine specific aminoendopeptidase and separating the material with insulinlike activity from the enzyme, lysyl-alanine and oligopeptides.
  • the products and polypeptides of the invention have insulin-like activity and also cause a significantly smaller production of antibodies which bind insulin-like materials on subsequent administration than do the starting materials.
  • The'insulin-like activity is demonstrated by measuring the hypoglycaemic response produced by the products in rabbits using the technique set out in the United States Pharmacopeia, vol. 18, page 883. Equal weights of the products and the WHO. standard showed the same hypoglycaemic response within the accuracy of the method.
  • the smaller production of antibodies is demonstrated by administering the test compounds, dissolved in a 50:50 mixture of complete Freunds adjuvant and saline, to rabbits, and then, one month later, measuring the insulin binding capacity of the rabbits serum by adding a known amount of insulin labelled with to the serum and determining the amount of free and bound labelled insulin.
  • This procedure is based on known methods, for example from Schlichtkrull et al. Diabetes, vol. 21, Supplement 2, pages 649656 (1972).
  • the new polypeptides of the invention are used for the management of diabetes in essentially the same way as porcine or bovine insulin. Thus they are administered parenterally, usually subcutaneously, either as a solution or as depot formulations having differing durations of action. Such formulations allow for a duration of action for up to 24 hours. Doses are selected for individual patients as required for the control of the diabetic and may be as high as 200 units daily.
  • an injectable formulation comprising des-Lys -Ala porcine insulin or des-Lys -Ala wbovine insulin as the essential active ingredient.
  • EXAMPLE 2 Porcine insulin which had been crystallised 10 times was dissolved in 0.1 M ammonium bicarbonate co'n taining calcium chloride to give a solution containing 2 mg. of insulin per ml. and a calcium chloride concentration of 3 X 10 molar. Portions of this solution were then incubated at pH 8.2, 37C. for 40 hours with amounts of AM protease giving the following.enzyme/- substrate ratios: l/625, l/1250, M2500 .and H5000. Analysis of the incubation mixtures at intervals by the techniques described in Example 1 showed completed cleavage in each case apart from the -l/ 5000 reaction where 88% cleavage was obtained at the end of the expcriment.
  • EXAMPLE 3 Porcine insulin which had been crystallised l0 times was dissolved in buffers prepared from ammonia and acetic acid of pH 4.0. 6.0, 8.0 and 10.0 containing calcium chloride to give 2 mg'./ml. of insulin'and' 3 X YO molar calcium chloride. The solutions were incubated with AM protease at a 17100 enzyme/substrate ratio at 37C. for o'hours'Analysis as in Example 2 showed that cleavage was takingplace in each case.
  • Porcine insulin which had been crystallised 10 times was dissolved in 0.1 M ammonium bicarbonate buffer of pH 8.2 containing calcium chlorideto give a solution containing 2 mg./ml. of insulin and 3 X 10' molar calcium chloride. Portions of the solution were incubated with AM protease at an enzyme/substrate ratio of l/l000 for 3 hours at temperatures of 23C., 37C., 45C., and 55C. Analysis as in Example 2 showed complete cleavage at 37C. and 45C., approximately 50% cleavage at 55C. and a small amount of cleavage at 23C.
  • EXAMPLE-'5 A solution of porcine insulin mg. once crystallised porcine insulin purified by gel filtration (Sephadex G.50) in 0.1 M ammonium carbonate] in water (14 ml.). adjusted to pH 8.0 and containing 3 X 10 M calcium chloride was incubated at 37C. with AM protease 120 ug.) for 5 hours. During the incubation, the pH was kept at 8.0 by the automatic addition of 0.005 M sodium hydroxide solution. The resulting solution was applied to a column 100 X 1.4 cm.) of porous cross-linked dextran gel (Sephadex G50) and the column developed with 0.1 M ammonium carbonate at a flow rate of 13 ml./hr.
  • the agarose gel having AM protease bound to it was prepared as followsr utzsion of 3 ml. of 4% agarose gel beads (Sepharose' 4B) in 10 ml. of water was stirred with 450 mg. of cyanogen bromide for 20 minutes while the pH of the mixture was maintained at l0l l by the addition of 4N sodium hydroxide. The suspension was then mixed with ice and washed with 2 l. of a cold pH 8.0 buffer solution containing sodium bicarbonate 0.1 M)
  • the washed sus-- pension was then stirred with 13.5 ml. of a solution of AM protease mg.) in the above pH 8.0 buffer at 4C. for 12 hours.
  • the solid was washed with I l. of the above pH 8.0 buffer, and then kept in a l M solution of ethanolamine at pH 8.0 for 2 hours.
  • the solid was washed with (a) 0.1 M sodium acetate/acetic acid buffer of pH 4.0 containing 1.0 M sodium chloride and then (b) 0.1 M sodium borate buffer of pH 8.5 containing 1.0 M sodium chloride. and the washings with (a) and then (b) repeated four times.
  • the agarose beads containing convalently bound enzyme were then equilibrated with 0.1 M ammonium bicarbonate of pH 8.2.
  • EXAMPLE 7 Solutions of porcine insulin X crystallised) containing l mg./ml. were incubated at pH 8.0 and 40C. for 2 hours with AM protease at an enzyme/substrate ratio of l/1000 in the presence of magnesium chloride at concentrations of IO", 10*, I0 and [0 molar respectively. Analysis as in Example 2 showed 90% cleavage with 10 molar Mg, 75% cleavage with 10' and 10 molar Mg. and 65% cleavage with 10 molar Mg. In the absence of magnesium, 68% cleavage took place.
  • EXAMPLE 8 A solution of crystalline bovine insulin 150 mg.) in water (2 ml.). adjusted to pH 8.3 and containing 10 M calcium chloride, was incubated with AM protease (140 ug.) for 3 hours at 37C. During the incubation, the pH was kept at 8.3 by the automatic addition of 0.02 M sodium hydroxide solution. An aliquot of the solution (10 I.) was examined using the amino-acid analyser as described in example I, but with the programme l min. (pH 3.28), l min. (pH 4.25), 60 min. (pH 6.65) then the column regeneration cycle.
  • the insulin peak (elution time 90 min.) was absent, whereas des-Lys -Ala -bovine insulin (elution time 80 min.) and Lys-Ala (elution time 120 min.) were both present.
  • the incubated solution was then lyophilised, and the solid dissolved in M acetic acid (2 ml.). This solution was subjected to gel filtration at 4C. as described in example 5 but with M acetic acid as solvent.
  • the fractions comprising the main peak as measured by UN. absorption at 280 nm. were combined and lyophilysed to give des-Lys *-Ala"-bovine insulin I 13 mg.).
  • EXAMPLE 9 Once crystallized porcine insulin I50 mg. was dissolved in water by the addition of N ammonium hydroxide, and the solution made up to 3.0 ml. with 0.1M ammonium bicarbonate. AM protease solution (150 pg, 0.5 ml.) was added, and the solution was kept at 37C. for l 1 hours. Analysis of an aliquot of the digest by the technique described in Example 8 showed that digestion was complete. The solution was diluted with 40% v/v aqueous acetic acid (3 ml.). and the resulting solution was applied to a column of Sephadex G 50 160 X 2.0 cm..).
  • R is threonine and R is isoleucine, or R is alanine and R is valine.
  • a product having insulin-like activity but being less effective in causing the production of antibodies which bind insulin-like materials on subsequent admin-' istration than porcine insulin as normally available said product being obtained by exposing the porcine insulin as normally available in an aqueous medium to the action of a lysine specific amino-endopeptidase and then separating the material with insulin-like activity from the enzyme, lysyl-alanine and oligopeptides formed by cleavage of impurities present in the porcine insulin as normally available.
  • a product having insulin-likeactivity but being less effective in causing the production of antibodies which bind insulin-like materials on subsequent administration than bovine insulin as normally available said product being obtained by exposing the bovine insulin as normally available in an aqueous medium to the action of a lysine specific amino-endopeptidase and then separating the material with insulin-like activity from the enzyme, lysyl-alanine and oligopeptideo formed by cleavage of impurities present in the bovine insulin as normally available.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
US420573A 1972-12-28 1973-11-30 Polypeptides obtained by modification of porcine or bovine insulin Expired - Lifetime US3903069A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB5974272 1972-12-28
GB438773*[A GB1426061A (en) 1972-12-28 1973-01-29 Polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US05/573,027 Division US3989821A (en) 1972-12-18 1975-04-30 Polypeptides

Publications (1)

Publication Number Publication Date
US3903069A true US3903069A (en) 1975-09-02

Family

ID=26239087

Family Applications (1)

Application Number Title Priority Date Filing Date
US420573A Expired - Lifetime US3903069A (en) 1972-12-28 1973-11-30 Polypeptides obtained by modification of porcine or bovine insulin

Country Status (18)

Country Link
US (1) US3903069A (US20030204162A1-20031030-M00001.png)
JP (1) JPS5726760B2 (US20030204162A1-20031030-M00001.png)
AT (1) AT348152B (US20030204162A1-20031030-M00001.png)
AU (1) AU474971B2 (US20030204162A1-20031030-M00001.png)
CA (1) CA1009974A (US20030204162A1-20031030-M00001.png)
CH (1) CH599927A5 (US20030204162A1-20031030-M00001.png)
DD (1) DD110490A5 (US20030204162A1-20031030-M00001.png)
DE (1) DE2364883C2 (US20030204162A1-20031030-M00001.png)
ES (1) ES421864A1 (US20030204162A1-20031030-M00001.png)
FR (1) FR2212136B1 (US20030204162A1-20031030-M00001.png)
GB (1) GB1426061A (US20030204162A1-20031030-M00001.png)
HU (1) HU170437B (US20030204162A1-20031030-M00001.png)
IE (1) IE38539B1 (US20030204162A1-20031030-M00001.png)
IL (1) IL43751A (US20030204162A1-20031030-M00001.png)
LU (1) LU69075A1 (US20030204162A1-20031030-M00001.png)
NL (1) NL7317159A (US20030204162A1-20031030-M00001.png)
PL (1) PL91158B1 (US20030204162A1-20031030-M00001.png)
SE (1) SE404600B (US20030204162A1-20031030-M00001.png)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4320197A (en) * 1979-04-13 1982-03-16 Shionogi & Co., Ltd. Semi-synthesis of human insulin
US5070186A (en) * 1986-10-20 1991-12-03 Novo Industri A/S Magnesium containing insulin solution
US5164366A (en) * 1988-12-23 1992-11-17 Novo Nordisk A/S Human insulin analogues
US5716927A (en) * 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
US6673347B1 (en) 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
US20070037967A1 (en) * 1986-04-30 2007-02-15 Amylin Pharmaceuticals, Inc. Polypeptide and protein derivatives and process for their preparation

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK146482C (da) * 1979-04-13 1986-10-06 Shionogi & Co Fremgangsmaade til fremstilling af et b30-threonin-insulin
EP0087238A1 (en) * 1982-02-08 1983-08-31 Biogen N.V. Am improved method for preparing human insulin from non-human insulin
DE3209184A1 (de) * 1982-03-13 1983-09-15 Hoechst Ag, 6230 Frankfurt Verfahren zur umwandlung von praeproinsulinanaloga zu insulinen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH471220A (de) * 1964-05-09 1969-04-15 Roehm & Haas Gmbh Verfahren zur Herstellung einer L-Leucinamid, Hypertensin und Oxytocin spaltenden Aminopeptidase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Brandenburg et al.: "Protein and Polypeptide Hormones," Margoulies, ed., Excerpta Medica, Amsterdam, 1969, pp. 482-484 *
Prout: Metabolism, 12, 673-675, (1963) *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4320197A (en) * 1979-04-13 1982-03-16 Shionogi & Co., Ltd. Semi-synthesis of human insulin
US4401757A (en) * 1979-04-13 1983-08-30 Shionogi & Co., Ltd. Semi-synthesis of human insulin
US6673347B1 (en) 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
US20040081660A1 (en) * 1986-04-30 2004-04-29 Offord Robin Ewart Polypeptide and protein derivatives and process for their preparation
US7129327B2 (en) 1986-04-30 2006-10-31 Amylin Pharmaceuticals, Inc. Polypeptide and protein derivatives and process for their preparation
US20070037967A1 (en) * 1986-04-30 2007-02-15 Amylin Pharmaceuticals, Inc. Polypeptide and protein derivatives and process for their preparation
US7538182B2 (en) 1986-04-30 2009-05-26 Amylin Pharmaceuticals, Inc. Polypeptide and protein derivatives and process for their preparation
US5070186A (en) * 1986-10-20 1991-12-03 Novo Industri A/S Magnesium containing insulin solution
US5164366A (en) * 1988-12-23 1992-11-17 Novo Nordisk A/S Human insulin analogues
US5716927A (en) * 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain

Also Published As

Publication number Publication date
ATA1084473A (de) 1978-06-15
FR2212136A1 (US20030204162A1-20031030-M00001.png) 1974-07-26
CH599927A5 (US20030204162A1-20031030-M00001.png) 1978-06-15
IL43751A (en) 1977-01-31
ES421864A1 (es) 1976-08-01
NL7317159A (US20030204162A1-20031030-M00001.png) 1974-07-02
IL43751A0 (en) 1974-03-14
JPS4994698A (US20030204162A1-20031030-M00001.png) 1974-09-09
GB1426061A (en) 1976-02-25
IE38539B1 (en) 1978-04-12
JPS5726760B2 (US20030204162A1-20031030-M00001.png) 1982-06-07
IE38539L (en) 1974-06-28
HU170437B (US20030204162A1-20031030-M00001.png) 1977-06-28
FR2212136B1 (US20030204162A1-20031030-M00001.png) 1978-01-06
CA1009974A (en) 1977-05-10
AU474971B2 (en) 1976-08-05
DD110490A5 (US20030204162A1-20031030-M00001.png) 1974-12-20
AU6297973A (en) 1975-05-29
AT348152B (de) 1979-02-12
DE2364883C2 (de) 1984-07-19
SE404600B (sv) 1978-10-16
DE2364883A1 (de) 1974-07-04
LU69075A1 (US20030204162A1-20031030-M00001.png) 1974-03-07
PL91158B1 (US20030204162A1-20031030-M00001.png) 1977-02-28

Similar Documents

Publication Publication Date Title
PIERCE et al. Studies on the structure of thyrotropin: its relationship to luteinizing hormone
Ong et al. The amino-terminal sequence of porcine pepsinogen
US4038222A (en) Untriakontapeptide with opiate activity
US4877614A (en) Biologically active fragments of human antihemophilic factor and method for preparation thereof
Katsoyannis et al. Studies on the synthesis of insulin from natural and synthetic A and B chains. III. Synthetic insulins
JPH0764875B2 (ja) 血液凝固阻害作用を有する新規ポリペプチド
US3664925A (en) Clinically active bovine growth hormone fraction
Strydom et al. Snake Venom Toxins: PURIFICATION, PROPERTIES, AND COMPLETE AMINO ACID SEQUENCE OF TWO TOXINS FROM RINGHALS (HEMACHATUS HAEMACHATUS) VENOM
CA2187083A1 (fr) Fragment peptidique de la proteine g du virus respiratoire syncytial, agent immunogene, composition pharmaceutique le contenant et procede de preparation
Cornell et al. The subunits of human pituitary thyroid-stimulating hormone: isolation, properties, and composition
PAPKOFF et al. Studies on the structure and function of interstitial cell-stimulating hormone
Marriq et al. Amino acid sequence of the unique 3, 5, 3′-triiodothyronine-containing sequence from porcine thyroglobulin
Joubert Snake venom toxins: the amino acid sequences of two toxins from Ophiophagus hannah (King Cobra) venom
US4056520A (en) Clinically active bovine growth hormone fraction
US3903069A (en) Polypeptides obtained by modification of porcine or bovine insulin
Dixon et al. The isolation and structure of α-melanocyte-stimulating hormone from horse pituitaries
JP2729498B2 (ja) ヒトインシユリンアナログ類
CA1244366A (en) Anti-diabetic compounds
Markussen et al. Rat‐Proinsulin C‐Peptides: Amino‐Acid Sequences
Free et al. Separation and properties of multiple components of bovine growth hormone
Lind et al. Complete Amino‐Acid Sequence of a Non‐neurotoxic, Non‐enzymatic Phospholipase A2 Homolog from the Venom of the Australian Tiger Snake Notechis scutatus scutatus
Chen et al. Purification and characteristics of porcine growth hormone
CA1243972A (en) Anti-diabetic compounds
Yamaji et al. On the biosynthesis of insulin in anglerfish islets
US3989821A (en) Polypeptides